Turnaround times
The quoted turnaround time is from sample receipt in the laboratory, to results authorisation in the Laboratory Information Management system. The times do not include transport of specimen to the laboratory or the administrative process to print and post/email reports. Service users must allow for transport and reporting time when ordering tests.
Clinical background:
Emicizumab (Hemlibra) is a bispecific monoclonal antibody used for the prophylaxis of bleeds in patients with Haemophilia A. Emicizumab works by bridging activated Factor IX and Factor X to restore the function of the missing activated Factor VIII. The Emicizumab assay is a modified one-stage APTT based assay used to determine plasma levels of the Emicizumab.
Specimen container paediatric:
Light blue – sodium citrate
Specimen container adult:
Light blue – sodium citrate
Minimum volume paediatric:
1.3 ml
Minimum volume adult:
2.7ml
Special requirements:
Tube must be correctly filled to line, to ensure correct ratio of blood to anticoagulant, ensure adequate mixing.
Sample Stability:
4 hrs
Transport requirements:
Samples should be transported to lab without delay
Freq Analysis:
On request
Add On Test:
[email protected] (external)
Quality Assurance:
UK NEQAS Emicizumab Supplementary Assay
Reference Ranges:
The expected on treatment levels after the patient has moved onto the maintenance dose (fortnightly injection) is in the range 40 – 60 µg/mL (Manufacturer data)